C/EBPα: Critical at the origin of leukemic transformation

Journal of Experimental Medicine

Volumn 211, Issue 1, 2014, Pages 1-4

  Roe, Jae Seok ^a   Vakoc, Christopher R ^a  

^a Simons Center for Quantitative Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME TRANSLOCATION; COLONY FORMATION; GENE REARRANGEMENT; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; MYELOID PROGENITOR CELL; MYELOPOIESIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN METHYLATION; SHORT SURVEY; TRANSLATION INITIATION;

CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL TRANSFORMATION, NEOPLASTIC; FEEDBACK, PHYSIOLOGICAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; MYELOID-LYMPHOID LEUKEMIA PROTEIN; MYELOPOIESIS;

EID: 84892550999     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20132530     Document Type: Short Survey

References (31)

1. Ablain, J., M. Leiva, L. Peres, J. Fonsart, E. Anthony, and H. de Thé. 2013. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J. Exp. Med. 210:647-653. http://dx.doi.org/10.1084/jem.20122337.
2. Armstrong, S.A., J.E. Staunton, L.B. Silverman, R. Pieters, M.L. den Boer, M.D. Minden, S.E. Sallan, E.S. Lander, T.R. Golub, and S.J. Korsmeyer. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30:41-47. http://dx.doi.org/10.1038/ng765.
3. Calkhoven, C.F., C. Müller, and A. Leutz. 2000. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev. 14:1920-1932.
4. Harris, W.J., X. Huang, J.T. Lynch, G.J. Spencer, J.R. Hitchin, Y. Li, F. Ciceri, J.G. Blaser, B.F. Greystoke, A.M. Jordan, et al. 2012. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 21:473-487. http://dx.doi.org/10.1016/j.ccr.2012.03.014.
5. Huang, Y., K. Sitwala, J. Bronstein, D. Sanders, M. Dandekar, C. Collins, G. Robertson, J. MacDonald, T. Cezard, M. Bilenky, et al. 2012. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood. 119:388-398. http://dx.doi.org/10.1182/blood-2011-03-341081.
6. Jin, S., H. Zhao, Y. Yi, Y. Nakata, A. Kalota, and A.M. Gewirtz. 2010. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Invest. 120:593-606. http://dx.doi.org/10.1172/JCI38030.
7. Kirstetter, P., M.B. Schuster, O. Bereshchenko, S. Moore, H. Dvinge, E. Kurz, K. Theilgaard-Mönch, R. Månsson, T.A. Pedersen, T. Pabst, et al. 2008. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell. 13:299-310. http://dx.doi.org/10.1016/j.ccr.2008.02.008.
8. Krivtsov, A.V., and S.A. Armstrong. 2007. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer. 7:823-833. http://dx.doi.org/10.1038/nrc2253.
9. Krivtsov, A.V., D. Twomey, Z. Feng, M.C. Stubbs, Y. Wang, J. Faber, J.E. Levine, J. Wang, W.C. Hahn, D.G. Gilliland, et al. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 442:818-822. http://dx .doi.org/10.1038/nature04980.
10. Kroon, E., J. Krosl, U. Thorsteinsdottir, S. Baban, A.M. Buchberg, and G. Sauvageau. 1998. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 17:3714-3725. http://dx.doi.org/10.1093/emboj/17.13.3714.
11. Lin, C., E.R. Smith, H. Takahashi, K.C. Lai, S. Martin-Brown, L. Florens, M.P. Washburn, J.W. Conaway, R.C. Conaway, and A. Shilatifard. 2010. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell. 37:429-437. http://dx.doi.org/10.1016/j.molcel.2010.01.026.
12. Mohan, M., C. Lin, E. Guest, and A. Shilatifard. 2010. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat. Rev. Cancer. 10:721-728. http://dx.doi .org/10.1038/nrc2915.
13. Nerlov, C. 2004. C/EBPalpha mutations in acute myeloid leukaemias. Nat. Rev. Cancer. 4:394-400. http://dx.doi.org/10.1038/nrc1363.
14. Ohlsson, E., M.S. Hasemann, A. Willer, F.K.B. Lauridsen, N. Rapin, J. Jendholm, and B.T. Porse. 2013. Initiation of MLL-rearranged AML is dependent on C/EBPa. J. Exp. Med. 211:5-13.
15. Okada, Y., Q. Feng, Y. Lin, Q. Jiang, Y. Li, V.M. Coffield, L. Su, G. Xu, and Y. Zhang. 2005. hDOT1L links histone methylation to leukemogenesis. Cell. 121:167-178. http://dx.doi.org/10.1016/j.cell.2005.02.020.
16. Pabst, T., B.U. Mueller, N. Harakawa, C. Schoch, T. Haferlach, G. Behre, W. Hiddemann, D.E. Zhang, and D.G. Tenen. 2001a. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7:444-451. http://dx.doi.org/10.1038/86515.
17. Pabst, T., B.U. Mueller, P. Zhang, H.S. Radomska, S. Narravula, S. Schnittger, G. Behre, W. Hiddemann, and D.G. Tenen. 2001b. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat. Genet. 27:263-270. http://dx.doi.org/10.1038/85820.
18. Porse, B.T., T.A. Pederson, X. Xu, B. Lindberg, U.M. Wewer, L. Friis-Hansen, C. Nerlov, and C. Nerlov. 2001. E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell. 107:247-258. http://dx.doi .org/10.1016/S0092-8674(01)00516-5.
19. Rosenbauer, F., and D.G. Tenen. 2007. Transcription factors in myeloid development: balancing differentiation with transformation. Nat. Rev. Immunol. 7:105-117. http://dx.doi.org/10 .1038/nri2024.
20. Shih, A.H., O. Abdel-Wahab, J.P. Patel, and R.L. Levine. 2012. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer. 12:599-612. http://dx.doi.org/10.1038/nrc3343.
21. Shilatifard, A. 2012. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81:65-95. http://dx.doi.org/10.1146/annurev-biochem-051710-134100.
22. Slomiany, B.A., K.L. D'Arigo, M.M. Kelly, and D.T. Kurtz. 2000. C/EBPalpha inhibits cell growth via direct repression of E2FDP-mediated transcription. Mol. Cell. Biol. 20:5986-5997. http://dx.doi.org/10.1128/MCB.20.16.5986-5997.2000.
23. Somervaille, T.C., and M.L. Cleary. 2006. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 10:257-268. http://dx.doi.org/10.1016/j.ccr.2006.08.020.
24. Wagner, K., P. Zhang, F. Rosenbauer, B. Drescher, S. Kobayashi, H.S. Radomska, J.L. Kutok, D.G. Gilliland, J. Krauter, and D.G. Tenen. 2006. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc. Natl. Acad. Sci. USA. 103:6338-6343. http://dx.doi.org/10.1073/pnas.0508143103.
25. Wang, Z.Y., and Z. Chen. 2008. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 111:2505-2515. http://dx .doi.org/10.1182/blood-2007-07-102798.
26. Yokoyama, A., M. Lin, A. Naresh, I. Kitabayashi, and M.L. Cleary. 2010. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell. 17:198-212. http://dx.doi .org/10.1016/j.ccr.2009.12.040.
27. Zaret, K.S., and J.S. Carroll. 2011. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 25:2227-2241. http://dx.doi.org/10.1101/gad.176826.111.
28. Zhang, P., J. Iwasaki-Arai, H. Iwasaki, M.L. Fenyus, T. Dayaram, B.M. Owens, H. Shigematsu, E. Levantini, C.S. Huettner, J.A. Lekstrom-Himes, et al. 2004. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 21:853-863. http://dx.doi .org/10.1016/j.immuni.2004.11.006.
29. Zuber, J., I. Radtke, T.S. Pardee, Z. Zhao, A.R. Rappaport, W. Luo, M.E. McCurrach, M.M. Yang, M.E. Dolan, S.C. Kogan, et al. 2009. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23:877-889. http://dx.doi.org/10.1101/gad.1771409.
30. Zuber, J., A.R. Rappaport, W. Luo, E. Wang, C. Chen, A.V. Vaseva, J. Shi, S. Weissmueller, C. Fellmann, M.J. Taylor, et al. 2011a. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated selfrenewal program as essential for leukemia maintenance. Genes Dev. 25:1628-1640. http://dx.doi.org/10.1101/gad.17269211.
31. Zuber, J., J. Shi, E. Wang, A.R. Rappaport, H. Herrmann, E.A. Sison, D. Magoon, J. Qi, K. Blatt, M. Wunderlich, et al. 2011b. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 478:524-528. http://dx.doi.org/10.1038/nature10334.